JERSEY CITY, N.J., April 11, 2019 /PRNewswire/ -- WallachBeth
Capital, a leading provider of capital markets and institutional
execution services, announced the closing of the initial public
offering of 1,250,000 shares of common stock at a public offering
price of $4.00 per share of Guardion
Health Sciences (NASDAQ:GHSI). The total offering was $5.0 million and shares began trading on the
Nasdaq Capital Market on Friday, April 5,
2019. Guardion has granted the underwriters a 45-day option
to purchase up to 187,500 additional shares of common stock at the
public offering price, less underwriting discounts and commissions,
to cover over-allotments, if any. WallachBeth Capital, LLC acted as
the lead manager for the IPO and WestPark Capital, Inc. acted as
co-manager.
A registration statement relating to the shares of common stock
sold in this offering was declared effective by the Securities and
Exchange Commission (the "SEC") on April
4, 2019. The offering was made only by means of a
prospectus. Copies of the final prospectus may be obtained on the
SEC's website, www.sec.gov, or by contacting WallachBeth Capital,
Attention: Capital Markets, Harborside Financial Center Plaza 5,
185 Hudson Street, Ste 1410, Jersey City
NJ 07311, by telephone at 646-998-7606, or by email at
cap-mkts@wallachbeth.com.
This press release does not constitute an offer to sell or a
solicitation of an offer to buy the securities described herein,
nor shall there be any sale of these securities in any state or
jurisdiction in which such an offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About Guardion Health Sciences, Inc.
Guardion is an ocular health sciences company that develops,
formulates and distributes condition-specific medical foods
supported by evidence-based protocols, with an initial medical food
product that addresses a depleted macular protective pigment, a
known risk factor for age-related macular degeneration ("AMD"), and
a significant component of functional vision performance. Guardion
Health Sciences, Inc. has also developed a proprietary medical
device, the MapcatSF®, which accurately measures the macular
pigment density, therefore providing the only two-pronged
evidence-based protocol for the treatment of a depleted macular
protective pigment.
About WallachBeth Capital LLC
WallachBeth Capital offers a robust range of capital markets and
investment banking services to the healthcare community, connecting
corporate clients with leading institutions, creating value for
both issuers and investors. Our origination experience
includes initial public offerings, follow-on issues, PIPE
offerings, and private transactions. The firm is a leading
provider of institutional execution services, offering clients a
full spectrum of solutions to help them navigate increasingly
complex markets. The firm's website is located at
www.wallachbeth.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/wallachbeth-capital-announces-completion-of-the-5-million-ipo-for-guardion-health-services-300830718.html
SOURCE WallachBeth Capital LLC